Clinical Trials | October 22, 2025
AbbVie's Rinvoq beats Humira in key arthritis trial
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Subscribe To Our Newsletter & Stay Updated
